GlassScriptPhysician profile
Konstantin Timofeev
NPI 1881853547
$3,061.81
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $125 · 2021: $2,163 · 2022: $644.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,426.24 | 2019-2021 | |
| Abbvie INC. | $311.41 | 2021-2022 | |
| Ucb, INC. | $262.95 | 2021-2022 | |
| Sk Life Science, INC. | $211.83 | 2021-2022 | |
| Eisai INC. | $160.04 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $126.20 | 2019-2022 | |
| Csl Behring | $102.11 | 2021-2022 | |
| Pfizer INC. | $91.47 | 2019-2022 | |
| Lilly USA, LLC | $47.37 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $41.49 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $36.80 | 2021 | |
| Neurelis, INC. | $32.09 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $25.42 | 2021 | |
| Biogen, INC. | $23.92 | 2021 | |
| Argenx US, INC. | $22.38 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.89 | 2020 | |
| Neuropace, INC. | $19.26 | 2019 | |
| Grifols USA, LLC | $17.18 | 2021 | |
| Upsher-Smith Laboratories LLC | $15.37 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.20 | 2022 | |
| Genentech USA, INC. | $13.87 | 2020 | |
| Allergan, INC. | $13.71 | 2021 | |
| Emd Serono, INC. | $13.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Konstantin Timofeev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.